• Resize Text
    • Small Text
    • Medium Text
    • Large Text
    • Connect
Central Nervous System
Central Nervous System

Rivastigmine Rosemont Oral Solution

Rivastigmine is an oral liquid medicine used to treat dementia.

Rivastigmine Oral Suspension is indicated for the following:

Symptomatic treatment of mild to moderately severe Alzheimer’s dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease.

Icon respresenting a network

Summary of Product Characteristics

Read this summary of product characteristics for further information about Rivastigmine Rosemont Oral Solution. Click below to navigate to the EMC.

More info
Icon respresenting a person

Patient Information Leaflet

Read this patient information leaflet about Rivastigmine Rosemont Oral Solution, what it’s used for and possible side effects. Click below to navigate to the EMC.

More info
Central Nervous System

Rivastigmine Rosemont Oral Solution

Rivastigmine Rosemont Oral Solution
Click here for Audio Version
Flavour None
Storage Conditions Do not store above 30°C. Do not refrigerate or freeze
Sucrose Free
Shelf Life (Closed Bottle/Open Bottle) 48 months / 1 month
PIP Code 120-2126
EAN Code 50-16119-31679-1
Sodium Levels Essentially sodium-free
Ethanol Concentration None

Downloads

Adverse Drug Events

Information about adverse event reporting can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Rosemont Pharmaceuticals Ltd on 0113 244 1400

Rosemont Pharmaceuticals - World Map icon

Contact us

For further product information and pricing please use the form below and a member of the team will be in touch






    Please prove you are human by selecting the heart.

    Stay updated via our App

     

    A new Rosemont Pharmaceuticals App for Healthcare Professionals is launching soon.

    Rosemont app on a mobile device

    Central Nervous System

    Rivastigmine Rosemont Oral Solution

    Rivastigmine Rosemont Oral Solution